Published in N Engl J Med on May 17, 1979
Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest (1980) 2.06
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood (2009) 1.85
Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. J Clin Invest (1980) 1.76
Hypothermia-induced reversible platelet dysfunction. Ann Surg (1987) 1.51
Arachidonate metabolism in vascular disorders. J Clin Invest (1983) 1.43
Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J (2011) 1.36
Bradykinin-induced, endothelium-dependent responses in porcine coronary arteries: involvement of potassium channel activation and epoxyeicosatrienoic acids. Br J Pharmacol (2005) 1.28
Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels. J Clin Invest (1984) 1.14
Effect of vasoactive peptides on prostacyclin synthesis in man. Br J Pharmacol (1986) 1.14
A nucleotide receptor in vascular endothelial cells is specifically activated by the fully ionized forms of ATP and UTP. Biochem J (1992) 1.10
Inhibitors of protein and RNA synthesis cause a rapid block in prostaglandin production at the prostaglandin synthase step. Proc Natl Acad Sci U S A (1986) 1.10
Maintenance of cardiodynamics with aspirin during abdominal aortic aneurysmectomy (AAA). Ann Surg (1981) 1.08
Kawasaki syndrome. Br Med J (Clin Res Ed) (1984) 1.06
Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. J Clin Invest (1984) 1.05
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood (2006) 1.03
Prostacyclin and thromboxane in diabetes. Br Med J (Clin Res Ed) (1981) 1.01
Determination of plasma malondialdehyde-like material and its clinical application in stroke patients. J Clin Pathol (1980) 1.01
Antiplatelet drugs. Br J Pharmacol (2006) 0.98
cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A (1988) 0.97
Photochemically induced cerebral infarction. II. Edema and blood-brain barrier disruption. Acta Neuropathol (1987) 0.97
Hypoxia-reoxygenation triggers coronary vasospasm in isolated bovine coronary arteries via tyrosine nitration of prostacyclin synthase. J Exp Med (1999) 0.94
Interleukin 1beta decreases prostacyclin synthase activity in rat mesangial cells via endogenous peroxynitrite formation. Biochem J (1998) 0.94
Responses of human, monkey and dog coronary arteries in vitro to carbocyclic thromboxane A2 and vasodilators. Br J Pharmacol (1984) 0.94
Thromboxane mediation of cardiopulmonary effects of embolism. J Clin Invest (1982) 0.93
Increased prostacyclin and thromboxane A2 biosynthesis in atherosclerosis. Proc Natl Acad Sci U S A (1988) 0.92
Prostaglandins in vascular disease: a seminal approach. Br Med J (Clin Res Ed) (1981) 0.90
Effects of mild physical exercise on serum lipoproteins and metabolites of arachidonic acid: a controlled randomised trial in middle aged men. Br Med J (Clin Res Ed) (1984) 0.90
Magnesium sulfate: rationale for its use in preeclampsia. Proc Natl Acad Sci U S A (1986) 0.90
Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics. Br J Pharmacol (1986) 0.90
Prostaglandin I₂promotes the development of IL-17-producing γδ T cells that associate with the epithelium during allergic lung inflammation. J Immunol (2011) 0.89
In-vitro venous prostacyclin production, plasma 6-keto-prostaglandin F1 alpha concentrations, and diabetic retinopathy. Br Med J (Clin Res Ed) (1981) 0.89
Pulmonary response of massive steroids in seriously injured patients. Ann Surg (1981) 0.88
Perturbation of cultured human endothelial cells by atherogenic levels of low density lipoprotein. Am J Pathol (1988) 0.88
Disorders of platelet function: mechanisms, diagnosis and management. West J Med (1981) 0.87
Influence of prostaglandin synthesis inhibitors on pulmonary vasodilatory effects of hydralazine in dogs with hypoxic pulmonary vasoconstriction. J Clin Invest (1981) 0.86
Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag (2009) 0.85
pH-dependent stimulation by Ca2+ of prostacyclin synthesis in rat aortic rings: effects of drugs and inorganic ions. Br J Pharmacol (1987) 0.84
Chronic exposure of cultured endothelial cells to eicosapentaenoic acid potentiates the release of endothelium-derived relaxing factor(s). Br J Pharmacol (1990) 0.84
Actions of amiloride analogues on prostacyclin synthesis by rat aortic rings. Br J Pharmacol (1987) 0.84
Survival of mice with NC carcinoma is unchanged by drugs that are thought to inhibit thromboxane synthesis or increase prostacyclin formation. Br J Cancer (1986) 0.84
Antiplatelet therapy--Part I. West J Med (1993) 0.84
Selective destruction of the outer leaflet of the capillary endothelial membrane after intracerebral injection of arachidonic acid in the rat. Acta Neuropathol (1982) 0.84
Abnormalities in the biosynthesis of thromboxane A2 and prostacyclin in children with cyanotic congenital heart disease. Br Heart J (1993) 0.83
Ibuprofen in acute-care therapy. Ann Surg (1990) 0.83
Prostaglandin I2 (prostacyclin). Can Med Assoc J (1980) 0.82
Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. Heart (1997) 0.82
The role of endothelial cells in the relaxations induced by 13-hydroxy- and 13-hydroperoxylinoleic acid in canine arteries. Br J Pharmacol (1992) 0.81
Effect of nicotine on production of prostacyclin in human umbilical artery. Br Heart J (1982) 0.81
Helicobacter pylori urease activates blood platelets through a lipoxygenase-mediated pathway. J Cell Mol Med (2009) 0.81
Aspirin and cardiovascular disease. Bull N Y Acad Med (1989) 0.81
Fish and coronary artery disease. Br Heart J (1987) 0.81
Reduction of primary nonfunction with prostaglandin E1 after clinical liver transplantation. Transplant Proc (1995) 0.80
Effect of intracardiac repair on biosynthesis of thromboxane A2 and prostacyclin in children with a left to right shunt. Br Heart J (1994) 0.79
Bradykinin B2 receptor antagonist FR173657 ameliorates small bowel ischemia-reperfusion injury in dogs. Dig Dis Sci (2005) 0.79
Prostanoid synthesis by aortic rings in human blood: selective increase of prostacyclin mediated by a serum factor. Br J Pharmacol (1984) 0.79
Autologous Platelet-Rich Plasma Preparations: Influence of Nonsteroidal Anti-inflammatory Drugs on Platelet Function. Orthop J Sports Med (2015) 0.78
Aspirin decreases platelet uptake on Dacron vascular grafts in baboons. Ann Surg (1984) 0.78
Angina and myocardial infarction with normal coronary arteries. Postgrad Med J (1991) 0.78
Prevention of cardiovascular disease: risks and benefits of aspirin. J Gen Intern Med (1990) 0.78
Platelet-vessel wall interactions: implication of 5-hydroxytryptamine. A review. Agents Actions (1984) 0.77
Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors. Br J Clin Pharmacol (1980) 0.77
Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol (2016) 0.77
Aspirin and myocardial infarction in young women. Am J Public Health (1982) 0.76
The effect of prolonged treatment with sulphinpyrazone on thromboxane A2 and prostacyclin in man. Br J Clin Pharmacol (1982) 0.75
Platelet aggregation in cerebral arterioles after percussive brain trauma. Tex Heart Inst J (1982) 0.75
Benefit-Risk Assessment of Fish Oil in Preventing Cardiovascular Disease. Drug Saf (2016) 0.75
International meeting on "Molecular biology of DNA repair." Presented by the British Photobiology Society and DNA Repair Information Network. 16-18 April, 1986, Manchester. Abstracts of posters. Br J Cancer (1986) 0.75
Effect of various doses of acetylsalicylic acid in combination with dipyridamole on the balance between prostacyclin and thromboxane in human serum. Br J Pharmacol (1981) 0.75
Prostaglandins in blister fluid after contact with an irritant and contact allergens. Arch Dermatol Res (1985) 0.75
Prostacyclin--powerful, yes: but is it useful? Br Med J (Clin Res Ed) (1983) 0.75
Neurology-important advances in clinical medicine: aspirin use in stroke therapy. West J Med (1982) 0.75
Recent advances in haematology. Postgrad Med J (1981) 0.75
Platelet glycoprotein IIb/IIIa blockade with tirofiban: effect on aggregation caused by P256, an antibody to human IIb/IIIa receptors. Br J Clin Pharmacol (1999) 0.75
Acetylsalicylic Acid in migraine with aura prevention - a retrospective study. Curr Health Sci J (2014) 0.75
Thrombosis: its role and prevention in cardiovascular events--Part I. Concepts of thrombogenesis and its prevention. West J Med (1981) 0.75
Comparative genome-wide transcriptional analysis of human left and right internal mammary arteries. Genomics (2014) 0.75
The urinary levels of prostanoid metabolites predict acute kidney injury in heterogeneous adult Japanese ICU patients: a prospective observational study. Clin Exp Nephrol (2015) 0.75
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41
Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature (1969) 13.60
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85
Prostaglandins: their disappearance from and release into the circulation. Nature (1967) 8.66
Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A (1989) 8.34
The release and fate of vaso-active hormones in the circulation. Br J Pharmacol (1969) 7.90
Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A (1989) 7.79
L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69
Prostaglandins released by the spleen. Nature (1968) 7.61
Nitric oxide synthases in mammals. Biochem J (1994) 6.50
A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30
Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 6.20
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A (1999) 5.96
Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol (1990) 5.87
Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36
Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23
A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun (1989) 5.14
The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol (1987) 4.88
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A (1993) 4.82
Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1988) 4.77
Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66
Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 4.55
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A (1990) 4.49
Inactivation of prostaglandins by the lungs. Nature (1970) 4.47
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23
Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19
Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11
An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74
Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74
Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J (1989) 3.70
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol (1972) 3.54
Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases. FEBS Lett (1991) 3.43
Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature (1972) 3.30
Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A (1995) 3.28
Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28
The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun (1987) 3.25
Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20
Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res (1992) 3.15
Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun (1990) 3.14
Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A (1998) 3.10
An improved method for washing of human platelets with prostacyclin. Thromb Res (1983) 3.07
A new approach to anti-inflammatory drugs. Biochem Pharmacol (1979) 2.95
Control of regional blood flow by endothelium-derived nitric oxide. Hypertension (1990) 2.93
Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A (1988) 2.84
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature (1991) 2.82
Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun (1991) 2.79
Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem Biophys Res Commun (1989) 2.73
Nitric oxide synthase activities in human myocardium. Lancet (1993) 2.72
Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A (1994) 2.70
Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol (1989) 2.68
Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67
The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci U S A (1990) 2.63
Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis (1992) 2.63
Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis (1989) 2.58
NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol (1989) 2.53
Arrest of preterm labour and prolongation of gestation with glyceryl trinitrate, a nitric oxide donor. Lancet (1994) 2.53
Pharmacokinetic function of the pulmonary circulation. Physiol Rev (1974) 2.52
The release of prostaglandins and rabbit aorta contracting substance (RCS) from rabbit spleen and its antagonism by anti-inflammatory drugs. Br J Pharmacol (1972) 2.52
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull (1978) 2.51
Prostaglandins, oxygen tension and smooth muscle tone. Br J Pharmacol (1972) 2.51
Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide. Biochem J (1992) 2.51
Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther (1973) 2.48
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br J Pharmacol Chemother (1967) 2.44
Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet (1992) 2.44
Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea-pig lungs. Br J Pharmacol (1973) 2.42
Phospholipase A2 activity of guinea-pig isolated perfused lungs: stimulation, and inhibition by anti-inflammatory steroids. Br J Pharmacol (1978) 2.41
S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol (1992) 2.39
The role of TH1 and TH2 cells in a rodent malaria infection. Science (1993) 2.38
The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci U S A (1995) 2.36
The contribution of prostaglandin production to contractions of the isolated uterus of the rat. Br J Pharmacol (1973) 2.33
Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol (1992) 2.32
Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol (1993) 2.32
Acetylcholine induces vasodilatation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodilator. Br J Pharmacol (1988) 2.32